News | 06 April 2021
Panacea to produce 100 mn doses of Sputnik V vaccine
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
The company had filed a suit in the High Court of Justice, Ghana
Integration of various regulatory agencies with a single-window system and putting in place a transparent, stable, predictable and easy to navigate interface.
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
Lupin will provide five lakh LupiSafe hand sanitizers to policemen and frontline workers deployed at strategic locations
NPPA also fixed retail price of 76 new drugs in the meeting dated 10th March 2021 to be launched by existing manufacturers including off-patent Anti-diabetic drugs allowing due benefit of patent expiry to the patients.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
Lonza Specialty Ingredients has become LifeClean’s first strategic industrial partner.
The vaccine was 85 percent effective in preventing severe disease across all regions.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80mg film coated tablets in India.
Subscribe To Our Newsletter & Stay Updated
